公开(公告)号：KR101117186B1

公开(公告)日：2012-03-07

申请号：KR1020110061540

申请日：2011-06-24

Applicant: 전남대학교산학협력단

Inventor： 홍철이 ,  이제중 ,  김미현

IPC: C12N5/0784 ,  C12N5/02 ,  C07K14/52

Abstract: PURPOSE: A method for enhancing cytotoxicity of cytotoxic T cells is provided to enhance mobility of dendritic cells to a second lymph organ and to induce maturation of novel dendritic cells. CONSTITUTION: A method for enhancing cytotoxicity of cytotoxic T cells comrises: a step of differentiating monocytes isolated from blood into immature dendritic cells; a step of treating antiviral cytokines, TLR activator, or mixture thereof to the immature dendritic cells to culture the immature dendritic cells; a step of treating a composition for enhancing mobility of dendritic cells to the immature dendritic cells to maturing the immature dendritic cells; and a step of adding IP-10(interferon-gamma inducible protein-10) to the matured dendritic cells.

Abstract translation: 目的：提供增强细胞毒性T细胞的细胞毒性的方法，以增强树突状细胞对第二淋巴管的迁移，并诱导新型树突状细胞的成熟。 构成：增强细胞毒性T细胞的细胞毒性的方法：将从血液中分离的单核细胞分化成未成熟树突状细胞的步骤; 将抗病毒细胞因子，TLR活化剂或其混合物处理至未成熟树突细胞以培养未成熟树突状细胞的步骤; 处理组合物以增强树突状细胞对未成熟树突细胞的迁移率以成熟未成熟树突状细胞的步骤; 以及向成熟树突状细胞中加入IP-10（干扰素-γ诱导型蛋白-10）的步骤。

公开(公告)号：KR101083404B1

公开(公告)日：2011-11-14

申请号：KR1020110036726

申请日：2011-04-20

Applicant: 전남대학교산학협력단

Inventor： 이제중 ,  홍철이 ,  김미현

IPC: C12N5/0784 ,  C12N5/02 ,  C07K14/52 ,  A61K38/19

Abstract: PURPOSE: A method for enhancing dendritic cell migration and ability of killing cytotoxic T cells is provided to improve migration of cendritic cells into a secondary lymphoid organ. CONSTITUTION: A composition for enhancing migration of dendritic cells contains chemokines including CCL21, CCL19, or mixture thereof. An active ingredient relates to migration of a secondary lymphoid organ by 10-250 ng/mL. A method for enhancing cell killing ability of cytotoxic T cells comprises a step of adding chemokine to monocytes during differenetion of immature dendritic cells into dendritic cells and culturing the dendritic cells.

Abstract translation: 目的：提供增强树突细胞迁移和杀死细胞毒性T细胞的能力的方法，以改善树突状细胞向次级淋巴器官的迁移。 构成：用于增强树突细胞迁移的组合物含有趋化因子，包括CCL21，CCL19或其混合物。 活性成分涉及二级淋巴器官的迁移10-250ng / mL。 增强细胞毒性T细胞杀伤细胞能力的方法包括在将未成熟树突细胞分化成树突状细胞并培养树突细胞的过程中向单核细胞中加入趋化因子。

公开(公告)号：KR100997753B1

公开(公告)日：2010-12-02

申请号：KR1020100013088

申请日：2010-02-12

Applicant: 전남대학교산학협력단

Inventor： 이제중 ,  홍철이 ,  이준행 ,  이현주

IPC: C12N5/0784 ,  C12N5/02 ,  C07K14/525 ,  C07K14/555

CPC classification number: C12N5/0639 ,  C07K14/525 ,  C07K14/555 ,  C12N1/38 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2501/998

Abstract: PURPOSE: A composition for inducing maturation of dendritic cells is provided to use as a therapeutic agent for tumor. CONSTITUTION: A composition for inducing maturation of dendritic cells contains bacteria flagellin, TNF-alpha, and interferone as active ingredients. A method for inducing maturation of immature dendritic cells comprises: a step of differentiating monocytes isolated from blood to immature dendritic cells; and a step of treating with bacteria flagellin, TNF-alpha and interferone to the immature dendtritic cells.

Abstract translation: 目的：提供一种用于诱导树突细胞成熟的组合物，用作肿瘤的治疗剂。 构成：用于诱导树突状细胞成熟的组合物含有细菌鞭毛蛋白，TNF-α和干扰素作为活性成分。 用于诱导未成熟树突状细胞成熟的方法包括：将从血液中分离的单核细胞分化成未成熟树突状细胞的步骤; 以及用细菌鞭毛蛋白，TNF-α和干扰素处理未成熟树突状细胞的步骤。

公开(公告)号：KR100982186B1

公开(公告)日：2010-09-14

申请号：KR1020100005405

申请日：2010-01-21

Applicant: 전남대학교산학협력단

Inventor： 이제중 ,  이현주 ,  홍철이

IPC: A61K38/16 ,  A61K39/235 ,  A61P35/00

CPC classification number: A61K39/0011 ,  A61K2039/5154 ,  A61K38/1764 ,  A61K39/235 ,  C07K14/4748 ,  Y10S514/885

Abstract: PURPOSE: A novel tumor antigen protein AGR2 and tumor antigenic peptide thereof are provided to induce tumor-specific cytotoxicity immune response. CONSTITUTION: A cellular immunotherapeutic agent composition for preventing or treating colorectal cancer comprises dendritic cells having human AGR2(anterior gradient-2) tumor antigenic peptide with an amino sequences of sequence number 6 or 12 or AGR2-specific cytotoxic T lymphocytes which is secreted from the dendritic cells as active ingredients. A method for manufacturing cellular immunotherapeutic agent composition for treating or preventing colorectal cancer comprises: a step of loading the human AGR2 tumor antigenic peptide; and a step of co-culturing the loaded dendritic cells and T lymphocytes.

Abstract translation: 目的：提供一种新的肿瘤抗原蛋白AGR2及其肿瘤抗原肽，以诱导肿瘤特异性细胞毒性免疫应答。 构成：用于预防或治疗结肠直肠癌的细胞免疫治疗剂组合物包含具有序列号6或12的氨基酸序列的人AGR2（前向梯度-2）肿瘤抗原肽或AGR2特异性细胞毒性T淋巴细胞的树突状细胞，其由 树突细胞作为活性成分。 用于制备用于治疗或预防结肠直肠癌的细胞免疫治疗剂组合物的方法包括：载入人AGR2肿瘤抗原肽的步骤; 以及共培养负载的树突状细胞和T淋巴细胞的步骤。